Onconova Therapeutics Performance
| ONTXDelisted Stock | USD 7.93 0.00 0.00% |
Onconova Therapeutics holds a performance score of 11 on a scale of zero to a hundred. The company holds a Beta of -3.33, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Onconova Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Onconova Therapeutics is expected to outperform it. Use Onconova Therapeutics total risk alpha, as well as the relationship between the downside variance and day median price , to analyze future returns on Onconova Therapeutics.
Risk-Adjusted Performance
11 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in Onconova Therapeutics are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Onconova Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 38.8 T |
Onconova |
Onconova Therapeutics Relative Risk vs. Return Landscape
If you would invest 69.00 in Onconova Therapeutics on January 20, 2024 and sell it today you would earn a total of 724.00 from holding Onconova Therapeutics or generate 1049.28% return on investment over 90 days. Onconova Therapeutics is currently generating 14.1847% in daily expected returns and assumes 96.6269% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Onconova, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Onconova Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Onconova Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Onconova Therapeutics, and traders can use it to determine the average amount a Onconova Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1468
| Best Portfolio | Best Equity | ONTX | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 96.63 actual daily | 96 96% of assets are less volatile |
Expected Return
| 5.07 actual daily | 96 96% of assets have lower returns |
Risk-Adjusted Return
| 0.15 actual daily | 11 89% of assets perform better |
Based on monthly moving average Onconova Therapeutics is performing at about 11% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Onconova Therapeutics by adding it to a well-diversified portfolio.
Onconova Therapeutics Fundamentals Growth
Onconova Stock prices reflect investors' perceptions of the future prospects and financial health of Onconova Therapeutics, and Onconova Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Onconova Stock performance.
| Return On Equity | -0.84 | |||
| Return On Asset | -0.38 | |||
| Operating Margin | (89.28) % | |||
| Current Valuation | (4.56 M) | |||
| Shares Outstanding | 21 M | |||
| Price To Earning | (0.87) X | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 92.50 X | |||
| Revenue | 226 B | |||
| EBITDA | (20.3 T) | |||
| Cash And Equivalents | 46.53 M | |||
| Cash Per Share | 2.23 X | |||
| Debt To Equity | 1.26 % | |||
| Book Value Per Share | 0.69 X | |||
| Cash Flow From Operations | (17.93 T) | |||
| Earnings Per Share | (0.96) X | |||
| Total Asset | 22.68 T | |||
| Retained Earnings | (482.63 T) | |||
| Current Asset | 23.18 M | |||
| Current Liabilities | 7.61 M | |||
About Onconova Therapeutics Performance
To evaluate Onconova Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Onconova Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Onconova Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Onconova Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents Onconova's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania. Onconova Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Things to note about Onconova Therapeutics performance evaluation
Checking the ongoing alerts about Onconova Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Onconova Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Onconova Therapeutics is now traded under the symbol TRAW. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Onconova Therapeutics is not yet fully synchronised with the market data | |
| Onconova Therapeutics is way too risky over 90 days horizon | |
| Onconova Therapeutics appears to be risky and price may revert if volatility continues | |
| Onconova Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 226 B. Net Loss for the year was (18.95 T) with profit before overhead, payroll, taxes, and interest of 226 K. | |
| Onconova Therapeutics currently holds about 46.53 M in cash with (17.93 T) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.23. | |
| Latest headline from seekingalpha.com: Onconova stock slips after all-stock merger |
- Analyzing Onconova Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Onconova Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Onconova Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Onconova Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Onconova Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Onconova Therapeutics' stock. These opinions can provide insight into Onconova Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Onconova Stock
If you are still planning to invest in Onconova Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Onconova Therapeutics' history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |